Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.
WALTHAM, Mass., Jan. 12, 2021 /PRNewswire/ -- Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ABBV), has licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019 designed to advance a number of Dragonfly's novel NK cell engager-based immunotherapies for autoimmune and oncology indications.
"AbbVie is committed to delivering improved treatment options to our patients" said Tom Hudson, M.D. Senior Vice President, R&D and Chief Scientific Officer at AbbVie. "The collaboration with Dragonfly has been remarkable. Working together, the teams have made rapid progress to develop this first TriNKET in record time."
"AbbVie is a global leader in treating immune-mediated diseases" said Bill Haney, co-founder and chief executive officer of Dragonfly, "they are a terrific partner and this opt-in, so soon after launching our collaboration, is a great vote of confidence. We look forward to continued success and rapid progress with the AbbVie team to advance new treatment options for patients."
The opt-in grants AbbVie exclusive worldwide intellectual property rights to develop and commercialize products directed to this first specific target, developed using Dragonfly's TriNKET™ technology platform. Dragonfly will receive an opt-in payment, as well as potential future development milestone payments and royalties from the sales of any commercialized candidates.
About Dragonfly Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough cancer treatments to patients.
For more information visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne Deconinck | anne@dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
Installing a retractable roof can help homeowners make better use of outdoor property without constructing a completely enclosed room. The system can provide overhead coverage when needed while preserving the open-air character of the patio. This approach is useful for residents who want additional living space but still value natural ventilation and outdoor views. Careful planning can ensure that the https://cabriostructures.com/ roof provides appropriate coverage while fitting the home's existing structure and supporting the intended activities.
Insightful podcast update with interesting points that keep readers informed about current events. The summary made it easy to follow and appreciate the broader context. I recently came across a similar discussion on a review blog, and it offered an interesting perspective as well. During some additional reading, https://www.aerospectny.com/ came up naturally in conversation. Thanks for sharing content that helps readers stay connected with ongoing developments and different viewpoints.
Encouraging update that highlights exciting developments in the field of therapeutics. The article explains the news clearly and keeps readers engaged throughout. I recently encountered another discussion where https://trgsupply.com/ was referenced naturally, offering an interesting comparison. Posts like this are valuable because they help readers stay informed about ongoing progress. Thank you for presenting the information in such an accessible and thoughtful way.
Informatively structured article that provided a great reading experience. I liked how the key points were explained with clarity and purpose. Not long ago, I noticed another discussion where https://firstclasswildliferemoval.com/ was mentioned naturally, which added a different perspective. Posts like this help readers stay curious and informed. Thank you for sharing something that is both educational and enjoyable to read.
Appreciate the clear breakdown of this update — biotech news like this can get pretty dense, but the key points were easy to follow. The collaboration and development angle is especially interesting in the immunotherapy space. I’ve been following similar industry discussions on a review blog https://gocollectiv.com/, which sometimes helps put these announcements into a broader research context. Thanks for sharing this update.